Background: GLE1 Biology and Research Significance

GLE1 (GLE1 RNA Export Mediator) is a conserved nucleoporin-associated protein that plays an indispensable role in the terminal steps of mRNA nuclear export. Localized at the cytoplasmic face of the nuclear pore complex (NPC), GLE1 functions as a co-activator of the DEAD-box RNA helicase DDX19B (the human ortholog of yeast Dbp5), stimulating its ATPase activity in a manner dependent on inositol hexakisphosphate (IP6). This GLE1–IP6–DDX19B axis is essential for directional mRNA export by remodeling messenger ribonucleoprotein (mRNP) complexes as they transit the NPC.

Beyond its canonical role in mRNA export, GLE1 has been implicated in the regulation of translation initiation and stress granule assembly, underscoring its importance across multiple aspects of RNA metabolism. Loss-of-function mutations in GLE1 are associated with lethal congenital contracture syndrome type 1 (LCCS1) and lethal arthrogryposis with anterior horn cell disease (LAAHD), highlighting the clinical relevance of studying this protein.

Recombinant Human GLE1 Protein enables in vitro biochemical characterization, protein–protein interaction studies, and structural analyses that would be difficult to perform with endogenous material.

Reconstitution and Storage Guidelines

Receipt and Initial Inspection: Upon receipt, briefly centrifuge the vial at low speed (≤1,000 × g for 10 seconds) to collect lyophilized material at the bottom before opening. Inspect for visible damage and confirm lot number against the certificate of analysis (CoA).

Reconstitution: Reconstitute lyophilized Recombinant Human GLE1 Protein in sterile, deionized water or an appropriate buffer (e.g., PBS, pH 7.4) to a working concentration as recommended on the product CoA. Add reconstitution solution slowly along the inner wall of the vial and gently swirl to dissolve — do not vortex, as this may cause protein aggregation or denaturation.

Working Aliquots: After reconstitution, prepare single-use aliquots to minimize freeze-thaw cycles. Store aliquots at -80°C for long-term use or at -20°C for short-term use (up to 4 weeks). Carrier protein (e.g., 0.1% BSA) may be added to stabilize the protein at low concentrations.

Avoid: Repeated freeze-thaw cycles (>2 cycles is not recommended), exposure to room temperature for prolonged periods, and storage in frost-free freezers that undergo temperature cycling.

Note: Always refer to the specific product CoA and datasheet for lot-specific reconstitution volumes and storage recommendations, as conditions may vary by formulation.

Recommended Experimental Applications

Recombinant Human GLE1 Protein is suitable for a range of in vitro research applications. The following uses are commonly reported in the scientific literature for GLE1 and related nucleocytoplasmic transport proteins:

• Protein–Protein Interaction Studies: Use GLE1 as bait or prey in pull-down assays, co-immunoprecipitation (co-IP) experiments, or surface plasmon resonance (SPR) to characterize interactions with DDX19B, NUP214, NUP155, and IP6.
• Helicase Activation Assays: Reconstitute the GLE1–IP6 complex in vitro to measure stimulation of DDX19B ATPase activity using colorimetric or radioactive phosphate-release assays.
• Structural Biology: Recombinant GLE1 protein can serve as antigen for antibody generation, or as a component in crystallography and cryo-EM studies of NPC cytoplasmic face assemblies.
• Functional Rescue Experiments: Use purified recombinant GLE1 to complement GLE1-depleted cell lysates or permeabilized cell systems to study mRNP remodeling at the NPC.
• ELISA and Western Blot Standards: Recombinant GLE1 can serve as a positive control or calibration standard in immunoassays detecting endogenous GLE1 expression.

Always validate experimental conditions empirically with appropriate positive and negative controls before committing to large-scale experiments.

Quality Control and Troubleshooting

Quality Control Checks: Before initiating downstream experiments, verify the integrity of the recombinant protein by SDS-PAGE or Western blot. The expected molecular weight of GLE1 should be consistent with the full-length human GLE1 isoform (approximately 79–84 kDa for the canonical sequence, though tag additions and post-translational modifications may alter apparent molecular weight). Confirm identity using an anti-GLE1 antibody or anti-tag antibody if the protein carries an affinity tag.

Common Issues and Solutions:

• Protein aggregation: If the solution appears turbid after reconstitution, centrifuge at 10,000 × g for 5 minutes at 4°C to remove aggregates. Consider adding mild detergents (e.g., 0.01% Tween-20) or reducing agents (e.g., 1 mM DTT) if recommended by the CoA.
• Low activity in helicase assays: Ensure IP6 is present at appropriate concentrations as a co-factor; confirm DDX19B substrate is correctly folded and RNA substrate is intact.
• Unexpected band sizes on SDS-PAGE: Minor additional bands may represent degradation products or glycosylation variants; refer to the CoA for expected purity and band pattern.
• Loss of activity after freeze-thaw: Minimize freeze-thaw cycles; add carrier protein (BSA) or glycerol (5–10%) as cryoprotectants.

Safety, Handling, and Disposal

General Safety: Recombinant Human GLE1 Protein is intended for research use only (RUO) and is not approved for diagnostic, therapeutic, or veterinary use. Handle all recombinant proteins with standard laboratory precautions, including the use of appropriate personal protective equipment (PPE): lab coat, gloves, and eye protection.

Biological Safety: While recombinant GLE1 is not classified as a known biohazard, it is produced in a recombinant expression system. Follow your institution's biosafety guidelines for handling recombinant proteins. Work in a biosafety cabinet if open handling of large volumes is required.

Chemical Hazards: Reconstitution buffers or stabilizers (e.g., DTT, PMSF) may pose additional chemical hazards; consult the relevant Safety Data Sheets (SDS) for all reagents used.

Disposal: Dispose of protein solutions and contaminated materials in accordance with local institutional and governmental regulations for biological and chemical waste. Do not pour protein solutions down the drain without prior treatment where regulations require.